Skip to main content

Table 4 Literature review of toxicity data

From: Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes

Study No. of Patients Therapy Median RT Dose Gy or CGE Median Follow-Up Years Toxicity Grading Scale G3+ GU Toxicity G2+ GU Toxicity G3+ GI Toxicity G2+ GI Toxicity
Liauw et al., 2009 [21] 130 IMRT 76 4.4 RTOG 6%b 37.0%b 5%b 14.0%b
Spratt et al., 2013 [22] 1002 IMRT 86.4 5.5 CTCAE 2.2% 8.5% 0.7% 2.0%
Vora et al., 2013 [23] 302 IMRT 75.6 7.6 CTCAE 2.6% 24.4% 1% 10.9%
Fang et al., 2015 [24] 94 IMRT 79.2 3.9 CTCAE 0% 18.3% 2.1% 10.8%
Fang et al., 2015 [24] 94 PS PBT 79.2 2.4 CTCAE 2.1% 12.8% 0% 12.8%
Slater et al., 2004 [17] 1255 PS PBT 74 5.3 RTOG 1.0%a 1.0%a
Pugh et al., 2013 [15] 291 PS > PBS PBT 76 2.0 RTOG 0%c 13.4%c 0.3%c 9.6%c
Mendenhall et al., 2014 [13] 211 PS PBT 78–82 5.2 CTCAE 1.0%a 0.5%a
Bryant et al., 2016 [9] 1215 PS PBT 78 5.5 CTCAE 2.9%a 0.6%a
Present study, 2017 192 PBS > PS PBT 79.2 1.7 CTCAE 1.0% 26.4%c 0.5% 21.3%c
  1. Abbreviations: PS passive scatter, PBS pencil beam scanning, PBT proton beam therapy, IMRT intensity-modulated radiation therapy, RTOG radiation therapy oncology group, CTCAE common terminology criteria for adverse events, version 4.0
  2. a = 5-year actuarial rate, b = 4-year actuarial rate, c = 2-year actuarial rate. No symbol next to a toxicity rate % indicates a rate reported as the number of toxicity events observed over the total number of patients, with varying median follow-up across studies